Karuna Therapeutics Inc
Change company Symbol lookup
Select an option...
KRTX Karuna Therapeutics Inc
PTOCU Pine Technology Acquisition Corp
BLUE bluebird bio Inc
ENSV Enservco Corp
ULIHF United Laboratories International Holdings Ltd
ABOIF Aboitiz Equity Ventures Inc
VYNE Vyne Therapeutics Inc
CEAD CEA Industries Inc
BFRI Biofrontera Inc
ARW Arrow Electronics Inc
Go

Health Care : Biotechnology | Small Cap Value
Company profile

Karuna Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on creating and delivering transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate, KarXT, is an oral modulator of muscarinic receptors that are located both in the central nervous system (CNS) and various peripheral tissues. It is initially developing KarXT, for the treatment of acute psychosis in patients with schizophrenia. The Company is for the treatment of psychosis in Alzheimer's disease (AD), which is the prevalent subtype of dementia-related psychosis (DRP). KarXT is a combination of xanomeline and trospium. It is advancing a pipeline of therapeutic programs to address the positive, negative and cognitive symptoms associated with schizophrenia and dementia-related psychosis (DRP). Its muscarinic receptors serve a number of physiological roles, including in cognitive, behavioral, sensory, motor and autonomic processes.

Price
Delayed
$131.17
Day's Change
5.07 (4.02%)
Bid
--
Ask
--
B/A Size
--
Day's High
131.93
Day's Low
123.70
Volume
(Light)

Today's volume of 237,544 shares is on pace to be much lighter than KRTX's 10-day average volume of 433,407 shares.

237,544

Company Profile

Karuna Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on creating and delivering transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate, KarXT, is an oral modulator of muscarinic receptors that are located both in the central nervous system (CNS) and various peripheral tissues. It is initially developing KarXT, for the treatment of acute psychosis in patients with schizophrenia. The Company is for the treatment of psychosis in Alzheimer's disease (AD), which is the prevalent subtype of dementia-related psychosis (DRP). KarXT is a combination of xanomeline and trospium. It is advancing a pipeline of therapeutic programs to address the positive, negative and cognitive symptoms associated with schizophrenia and dementia-related psychosis (DRP). Its muscarinic receptors serve a number of physiological roles, including in cognitive, behavioral, sensory, motor and autonomic processes.

Valuation Ratios

Price/Earnings (TTM)
--
Price/Sales (TTM)
101.94x
Price/Book (MRQ)
8.29x
Price/Cash Flow (TTM)
--
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

Price Performance

Historic Growth and Share Detail

Historic Growth

No historic growth available.

Short Interest

June 2022
Current Month
1.2M
Previous Month
1.0M
Percent of Float
4.30%
Days to Cover
4.4320 Days

Share Information

KRTX is in a share class of common stock
Float
27.7M
Shares Outstanding
29.9M
Institutions Holding Shares
249
99.01%

Financial Statements

Balance sheet

Values displayed are in millions.

Income statement

Values displayed are in thousands.

Cash flow

Values displayed are in thousands.

Company Officers

  • Steven M. PaulChmn.
  • Troy A. IgnelziCFO
  • Andrew Craig MillerCOO
  • Stephen BrannanOther
  • Charmaine LykinsOther

Address

Insider Trading

During the most recent quarter, 50 shares were bought, and 54K shares were sold in insider trading.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Insider trading information report provided by Copyright © 2022. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.